JPMorgan Chase & Co. Issues Pessimistic Forecast for GE HealthCare Technologies (NASDAQ:GEHC) Stock Price

GE HealthCare Technologies (NASDAQ:GEHC) had its price target cut by analysts at JPMorgan Chase & Co. from $80.00 to $65.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 6.50% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Barclays cut their price target on shares of GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating on the stock in a report on Thursday. Citigroup lowered their price objective on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday. Evercore set a $80.00 target price on shares of GE HealthCare Technologies in a research note on Thursday. Mizuho reduced their target price on shares of GE HealthCare Technologies from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Finally, Morgan Stanley lifted their price target on shares of GE HealthCare Technologies from $80.00 to $85.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Hold” and an average price target of $80.67.

GE HealthCare Technologies Price Performance

Shares of GEHC stock opened at $61.03 on Thursday. The stock has a 50 day moving average price of $73.28 and a 200 day moving average price of $77.52. GE HealthCare Technologies has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.13 and a current ratio of 1.22. The firm has a market capitalization of $27.76 billion, a P/E ratio of 14.60, a P/E/G ratio of 1.38 and a beta of 0.75.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period last year, the company earned $1.01 EPS. The business’s revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, sell-side analysts predict that GE HealthCare Technologies will post 4.84 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO James Saccaro bought 3,310 shares of the company’s stock in a transaction on Friday, May 1st. The shares were acquired at an average price of $60.60 per share, with a total value of $200,586.00. Following the transaction, the chief financial officer owned 87,471 shares of the company’s stock, valued at $5,300,742.60. The trade was a 3.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Peter J. Arduini purchased 4,169 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was bought at an average price of $59.92 per share, for a total transaction of $249,806.48. Following the completion of the acquisition, the chief executive officer directly owned 259,424 shares in the company, valued at approximately $15,544,686.08. This trade represents a 1.63% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 9,229 shares of company stock valued at $556,180 over the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On GE HealthCare Technologies

Institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC lifted its position in shares of GE HealthCare Technologies by 6.1% during the first quarter. Empowered Funds LLC now owns 28,848 shares of the company’s stock valued at $2,328,000 after buying an additional 1,665 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of GE HealthCare Technologies in the 1st quarter worth approximately $259,000. Cresset Asset Management LLC raised its stake in shares of GE HealthCare Technologies by 12.5% during the 2nd quarter. Cresset Asset Management LLC now owns 7,802 shares of the company’s stock worth $578,000 after acquiring an additional 865 shares in the last quarter. Jump Financial LLC raised its stake in shares of GE HealthCare Technologies by 317.6% during the 2nd quarter. Jump Financial LLC now owns 28,132 shares of the company’s stock worth $2,084,000 after acquiring an additional 21,396 shares in the last quarter. Finally, Gamco Investors INC. ET AL lifted its position in GE HealthCare Technologies by 8.6% during the second quarter. Gamco Investors INC. ET AL now owns 4,041 shares of the company’s stock valued at $299,000 after acquiring an additional 320 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

More GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Insiders are buying shares — CEO Peter Arduini, CFO James Saccaro and director Frank R. Jimenez increased positions (multiple Form 4 filings), which investors often interpret as management confidence in the company’s outlook. Read More. • Read More. • Read More.
• Positive Sentiment: Heavy call-option buying — an unusual surge in call volume suggests short-term bullish/speculative interest that can amplify upside moves. (No article link available)
• Neutral Sentiment: Wells Fargo lowered its price target to $75 but kept an overweight rating, signaling upside exists vs. current levels while tempering near-term expectations. Read More.
• Neutral Sentiment: Operational changes — GEHC announced a reorganization (Imaging + Advanced Visualization) and executive moves intended to improve execution; benefits could take multiple quarters to materialize. Read More.
• Negative Sentiment: Guidance cut and margin pressure — management trimmed FY26 EPS guidance to $4.80–5.00, citing inflation, higher component and freight costs and supply issues; this is the core reason for recent downside pressure. Read More.
• Negative Sentiment: Mixed Q1 results — revenue beat (~$5.13B) but EPS missed ($0.99 vs. $1.07 est.) and margins compressed, reinforcing short?term risk to earnings. Read More.
• Negative Sentiment: Analyst downgrades / price?target cuts — Citigroup, JPMorgan and others trimmed targets and ratings (e.g., PTs cut to ~$65–75), pulling sell?side support lower and contributing to volatility. Read More.
• Negative Sentiment: Investor litigation inquiry — a Johnson Fistel investigation adds headline and legal risk that could increase volatility. Read More.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.